Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Mar. 31, 2021
Current assets:
Cash and cash equivalents	$ 518,163	$ 674,493
Accounts receivable, net	14,402	3,570
Marketable securities	97,848	10,435
Inventories	6,141	2,611
Prepaid expenses and other current assets	18,112	13,536
Total current assets	654,666	704,645
Property and equipment, net	3,297	3,300
Operating lease right-of-use asset	8,835	9,655
Other assets	12,742	7,427
Total assets	679,540	725,027
Current liabilities:
Accounts payable	8,642	17,809
Accrued expenses and other current liabilities	46,334	44,612
Share-based compensation liabilities	5,769	21,636
Deferred revenue	100,564	100,564
Amounts due to Pfizer	19,957	1,954
Cost share advance from Pfizer	84,768	92,415
Operating lease liability	1,968	1,807
Amounts due to related parties	334	543
Total current liabilities	268,336	281,340
Deferred revenue, non-current	426,021	397,369
Cost share advance from Pfizer, non-current	0	29,447
Long-term operating lease liability	8,159	9,189
Long-term debt, less current maturities (related party)	358,700	358,700
Other liabilities	1,251	2,947
Total liabilities	1,062,467	1,078,992
Commitments and contingencies (Note 9)
Shareholders’ deficit:
Common shares, $0.000017727 par value, 564,111,242 shares authorized, 93,077,789 and 91,000,869 issued and outstanding at September 30, 2021 and March 31, 2021, respectively	2	2
Additional paid-in capital	763,755	709,466
Accumulated other comprehensive loss	(17,285)	(17,285)
Accumulated deficit	(1,129,399)	(1,046,148)
Total shareholders’ deficit	(382,927)	(353,965)
Total liabilities and shareholders’ deficit	$ 679,540	$ 725,027